GeneHealth - Your precision medicine

Gastrointestinal Anthrax

Disease Details

Family Health Simplified

Buy Membership

Description: Gastrointestinal anthrax is a rare but severe bacterial infection caused by ingesting Bacillus anthracis spores in contaminated food or water, leading to symptoms such as abdominal pain, vomiting, severe diarrhea, and bleeding.
Type: Gastrointestinal anthrax is an infectious disease caused by the bacterium Bacillus anthracis. It is not genetically transmitted; rather, it is acquired through the ingestion of undercooked or contaminated meat from infected animals.
Signs And Symptoms: Gastrointestinal anthrax is caused by the ingestion of Bacillus anthracis spores. Signs and symptoms typically appear within 1 to 7 days after exposure and can include:

- Nausea and vomiting, which may include blood
- Abdominal pain and swelling
- Loss of appetite
- Severe diarrhea, which may be bloody
- Fever
- Sore throat and difficulty swallowing
- Swollen neck

If untreated, gastrointestinal anthrax can lead to sepsis and be potentially fatal. Prompt medical treatment is crucial.
Prognosis: Cutaneous anthrax is rarely fatal if treated, because the infection area is limited to the skin, preventing the lethal factor, edema factor, and protective antigen from entering and destroying a vital organ. Without treatment, up to 20% of cutaneous skin infection cases progress to toxemia and death.Before 2001, fatality rates for inhalation anthrax were 90%; since then, they have fallen to 45%. People that progress to the fulminant phase of inhalational anthrax nearly always die, with one case study showing a death rate of 97%. Anthrax meningoencephalitis is also nearly always fatal.Gastrointestinal anthrax infections can be treated, but usually result in fatality rates of 25% to 60%, depending upon how soon treatment commences.
Injection anthrax is the rarest form of anthrax, and has only been seen to have occurred in a group of heroin injecting drug users.
Onset: The onset of gastrointestinal anthrax typically occurs within 1 to 7 days after ingesting the spores of the bacteria Bacillus anthracis. Symptoms can include severe abdominal pain, nausea, vomiting, diarrhea, and loss of appetite. If untreated, the condition can lead to serious complications and can be fatal.
Prevalence: Gastrointestinal anthrax is extremely rare. It is much less common than the cutaneous or inhalational forms of the disease. Specific prevalence data are not readily available due to its rarity and the infrequency of reported cases.
Epidemiology: Globally, at least 2,000 cases occur a year.
Intractability: Gastrointestinal anthrax can be severe and life-threatening, but it is not intractable. With early diagnosis and appropriate antibiotic treatment, the disease can be managed effectively. Delayed treatment, however, may lead to complications and a higher risk of mortality.
Disease Severity: Gastrointestinal anthrax is a severe bacterial infection caused by Bacillus anthracis. It affects the digestive system and occurs when a person consumes undercooked or contaminated meat from infected animals. The severity of gastrointestinal anthrax is high, with symptoms including severe abdominal pain, vomiting, bloody diarrhea, and fever. If not treated promptly with antibiotics, the condition can lead to systemic infection and septicemia, which can be fatal. Early diagnosis and treatment are crucial for improving outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:13386
Pathophysiology: Gastrointestinal anthrax is caused by ingesting Bacillus anthracis spores, typically from contaminated meat. Upon ingestion, the spores activate and release toxins. The pathophysiology involves the following steps:

1. **Spore Germination:** The spores germinate in the gastrointestinal tract.
2. **Toxin Production:** The bacteria produce lethal toxin (LT) and edema toxin (ET), which disturb cellular functions and cause tissue damage.
3. **Mucosal Invasion:** The bacteria penetrate the intestinal mucosa, leading to ulceration and necrosis.
4. **Systemic Spread:** B. anthracis can enter the bloodstream, resulting in septicemia and systemic toxin effects, which can cause severe complications, including shock and multi-organ failure.

The disease often presents with symptoms such as severe abdominal pain, vomiting, diarrhea (which can be bloody), and fever. Without prompt treatment, gastrointestinal anthrax can be fatal.
Carrier Status: Carrier status for gastrointestinal anthrax does not apply, as this disease is not known to have asymptomatic carriers that spread the infection. Gastrointestinal anthrax is an acute disease caused by ingesting the spores of Bacillus anthracis, typically through undercooked or contaminated meat from infected animals. The spores germinate in the gut, leading to severe gastrointestinal symptoms.
Mechanism: The lethality of the anthrax disease is due to the bacterium's two principal virulence factors: the poly-D-glutamic acid capsule, which protects the bacterium from phagocytosis by host neutrophils; and the tripartite protein toxin, called anthrax toxin, consisting of protective antigen (PA), edema factor (EF), and lethal factor (LF). PA plus LF produces lethal toxin, and PA plus EF produces edema toxin. These toxins cause death and tissue swelling (edema), respectively.
To enter the cells, the edema and lethal factors use another protein produced by B. anthracis called protective antigen, which binds to two surface receptors on the host cell. A cell protease then cleaves PA into two fragments: PA20 and PA63. PA20 dissociates into the extracellular medium, playing no further role in the toxic cycle. PA63 then oligomerizes with six other PA63 fragments forming a heptameric ring-shaped structure named a prepore. Once in this shape, the complex can competitively bind up to three EFs or LFs, forming a resistant complex. Receptor-mediated endocytosis occurs next, providing the newly formed toxic complex access to the interior of the host cell. The acidified environment within the endosome triggers the heptamer to release the LF and/or EF into the cytosol. It is unknown how exactly the complex results in the death of the cell.
Edema factor is a calmodulin-dependent adenylate cyclase. Adenylate cyclase catalyzes the conversion of ATP into cyclic AMP (cAMP) and pyrophosphate. The complexation of adenylate cyclase with calmodulin removes calmodulin from stimulating calcium-triggered signaling, thus inhibiting the immune response. To be specific, LF inactivates neutrophils (a type of phagocytic cell) by the process just described so they cannot phagocytose bacteria. Throughout history, lethal factor was presumed to cause macrophages to make TNF-alpha and interleukin 1, beta (IL1B). TNF-alpha is a cytokine whose primary role is to regulate immune cells, as well as to induce inflammation and apoptosis or programmed cell death. Interleukin 1, beta is another cytokine that also regulates inflammation and apoptosis. The overproduction of TNF-alpha and IL1B ultimately leads to septic shock and death. However, recent evidence indicates anthrax also targets endothelial cells that line serous cavities such as the pericardial cavity, pleural cavity, and peritoneal cavity, lymph vessels, and blood vessels, causing vascular leakage of fluid and cells, and ultimately hypovolemic shock and septic shock.
Treatment: Anthrax cannot be spread from person to person, except in the rare case of skin exudates from cutaneous anthrax. However, a person's clothing and body may be contaminated with anthrax spores. Effective decontamination of people can be accomplished by a thorough wash-down with antimicrobial soap and water. Wastewater is treated with bleach or another antimicrobial agent. Effective decontamination of articles can be accomplished by boiling them in water for 30 minutes or longer. Chlorine bleach is ineffective in destroying spores and vegetative cells on surfaces, though formaldehyde is effective. Burning clothing is very effective in destroying spores. After decontamination, there is no need to immunize, treat, or isolate contacts of persons ill with anthrax unless they were also exposed to the same source of infection.
Compassionate Use Treatment: Compassionate use treatment and off-label or experimental treatments for gastrointestinal anthrax may include the use of antibiotics such as ciprofloxacin, doxycycline, or levofloxacin. Additionally, antitoxins like raxibacumab or obiltoxaximab, originally developed for inhalational anthrax, might be considered. Supportive care, including intravenous fluids, pain management, and surgical intervention for gastrointestinal complications, may also be necessary in severe cases.
Lifestyle Recommendations: To reduce the risk and manage gastrointestinal anthrax, consider the following lifestyle recommendations:

1. **Safe Food Practices**: Ensure that meat is properly cooked, especially if it comes from areas where anthrax is more common.
2. **Avoid Exposure**: Refrain from consuming meat from animals that have died of unknown causes or without proper inspection.
3. **Hygiene**: Maintain good personal hygiene, including thoroughly washing hands before food preparation and eating.
4. **Awareness**: Be aware of the symptoms of gastrointestinal anthrax, which can include severe abdominal pain, vomiting, and bloody diarrhea, and seek medical attention if such symptoms occur, especially following consumption of potentially contaminated meat.
5. **Preventive Measures**: If traveling to or residing in areas where anthrax is prevalent, follow local health guidelines and consult healthcare providers for recommendations, including possible vaccination or prophylactic antibiotics if indicated.

Always seek advice from healthcare professionals for comprehensive guidelines tailored to your situation.
Medication: Gastrointestinal anthrax is treated with antibiotics. The commonly used antibiotics include ciprofloxacin, doxycycline, or amoxicillin. Treatment typically involves a combination of intravenous and oral antibiotics, especially in severe cases. Early diagnosis and treatment are crucial for improving outcomes. The use of antitoxins may also be considered in some cases.
Repurposable Drugs: Repurposable drugs for gastrointestinal anthrax are limited due to the severity and specificity of the disease caused by Bacillus anthracis. However, some antibiotics used for other conditions might be effective in treatment. These include:

1. **Ciprofloxacin** - Typically used for various bacterial infections, it is one of the primary treatments for anthrax.
2. **Doxycycline** - Another antibiotic that is often repurposed for treating infections caused by Bacillus anthracis.
3. **Amoxicillin** - Can be considered for less severe cases or post-exposure prophylaxis, particularly if the strain is penicillin-sensitive.

These medications are usually more effective when administered early in the course of the disease and are often used in combination with antitoxin therapies to neutralize anthrax toxins.
Metabolites: For gastrointestinal anthrax, there are no specific metabolites unique to the disease that can be identified in standard clinical practice. Diagnosis is typically based on clinical features, history of exposure, and microbiological testing such as culture, PCR, or serologic assays.
Nutraceuticals: There is no established role for nutraceuticals in the treatment or prevention of gastrointestinal anthrax. The primary approach to managing this serious illness includes the use of antibiotics and supportive medical care. Early diagnosis and prompt antibiotic treatment are crucial for improving outcomes. If you have any specific questions or need more detailed information, please let me know.
Peptides: Gastrointestinal anthrax is caused by the bacterium Bacillus anthracis. Its primary toxin comprises three components: protective antigen (PA), lethal factor (LF), and edema factor (EF), which are proteins but can also be considered peptides as they are chains of amino acids. Protective antigen binds to host cells and facilitates the entry of lethal factor and edema factor into the cells. The condition often causes severe symptoms like nausea, vomiting, anorexia, and gastrointestinal bleeding, and can be fatal if not promptly treated.